Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
780 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00601146 | Low-Dose Chest Computed Tomography Screening for Lung Cancer in Survivors of Hodgkin's Disease | completed | N/A | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT01614821 | Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 21, 2020 | clinicaltrials |
| NCT02502695 |
| A Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS) |
| completed |
| — |
| 173 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| Jan 13, 2020 |
| clinicaltrials |
| NCT02969031 | Improving Communication Between Cancer Patients & Oncologists | completed | N/A | 148 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 3, 2020 | clinicaltrials |
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | withdrawn | Phase 2 | 0 | Dana-Farber Cancer InstituteOTHER | 0 | Dec 17, 2019 | clinicaltrials |
| NCT01894451 | Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy | completed | Early Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 12, 2019 | clinicaltrials |
| NCT02470910 | Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning | completed | N/A | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2019 | clinicaltrials |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | terminated | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT02661815 | A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer | terminated | Phase 1 | 6 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01184326 | Expanded Phase I Pazopanib and Everolimus in Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT02248662 | Impact of Radiation Therapy on Breast Conservation in DCIS | completed | — | 3,436 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01664091 | Cosmetic Result/Toxicity in Post-Mastectomy Immediate Reconstruction Expander+RT | completed | N/A | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT00376480 | Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | completed | Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT01740219 | Promoting Organizational Capacity to Implement Cancer Control Programs Among Latino Churches(CRUZA) | completed | N/A | 348 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 20, 2019 | clinicaltrials |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial | terminated | Phase 1 | 2 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 12, 2019 | clinicaltrials |
| NCT00153920 | Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma | completed | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT03887091 | Personal Web Page In Clinical Trial Participant Education | completed | N/A | 99 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01958112 | GSK1120212+GSK2141795 for Cervical Cancer | terminated | Phase 2 | 14 | Dana-Farber Cancer InstituteOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT00083031 | Metronomic Low-Dose Cyclophosphamide and Methotrexate With or Without Bevacizumab in Treating Women With Metastatic Breast Cancer | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | May 21, 2019 | clinicaltrials |
| NCT00165412 | Breast MRI Screening in Women Treated With Mediastinal Irradiation for Hodgkin's Disease | completed | — | 148 | Dana-Farber Cancer InstituteOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT01164956 | Methylphenidate for Cancer-Related Fatigue | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 26, 2019 | clinicaltrials |
| NCT01253369 | Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01286675 | Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization in Multiple Myeloma Patients Undergoing ASCT | completed | Early Phase 1 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 1, 2019 | clinicaltrials |
| NCT01741753 | BKM120+Abiraterone Acetate for Metastatic CRPC | terminated | Phase 1 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 5, 2019 | clinicaltrials |
| NCT00928018 | Tacrolimus/Sirolimus/Methotrexate vs Tacrolimus/Methotrexate or Cyclosporine/Mycophenolate Mofetil for GVHD Prophylaxis After Reduced Intensity Allogeneic Stem Cell Transplantation for Patients With Lymphoma | completed | Phase 3 | 139 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 1, 2019 | clinicaltrials |
| NCT01185509 | Trastuzumab and Vinorelbine in Advanced Breast Cancer | terminated | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01790932 | BKM120 For Triple Negative Breast Cancer | completed | Phase 2 | 50 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01319591 | Comparison of Creatinine Clearance Calculation for Estimation of GFR in Patients Receiving HD Methotrexate | completed | — | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT01786811 | Serious Illness Communication Project | completed | N/A | 994 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 22, 2019 | clinicaltrials |
| NCT00148681 | Preoperative Herceptin and Navelbine for Breast Cancer | completed | Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03132584 | Cyclophosphamide and Alemtuzumab In Lymphoma | terminated | Phase 1 | 3 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 14, 2019 | clinicaltrials |
| NCT00611858 | Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01004172 | Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases | completed | Phase 2 | 38 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 14, 2018 | clinicaltrials |
| NCT00020605 | Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain | unknown | Phase 3 | — | Dana-Farber Cancer InstituteOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT02452710 | Harnessing the Effect of an Open-Label Placebo on Fatigue in Cancer Survivors | terminated | N/A | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT02756390 | CBTI-CS: A Novel Cognitive-Behavioral Treatment for Insomnia in Cancer Survivors | completed | N/A | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT01912963 | Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer | terminated | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03291730 | A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology Setting | completed | N/A | 22 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT01470196 | Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia(CaRD) | completed | Phase 2 | 31 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT00788775 | Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00215501 | Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies | completed | Phase 1 | 54 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT00137813 | Avastin and Taxotere for Esophagogastric Cancer | completed | Phase 2 | 42 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 1, 2018 | clinicaltrials |
| NCT01829217 | Sunitinib in Never-Smokers With Lung Adenocarcinoma | completed | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01200238 | STA-9090(Ganetespib) in Metastatic Ocular Melanoma | completed | Phase 2 | 17 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 18, 2018 | clinicaltrials |
| NCT00976248 | Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT00880334 | Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | completed | Phase 2 | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials